Q3 2024 Earnings Call Transcript November 9, 2024 Operator: Good afternoon, everyone, and welcome to the Atea Pharmaceuticals Third Quarter 2024 Financial Results and Business Update Conference Call.

India needs to expand its local vaccine manufacturing and research to give better control over safety of these pharma ...

But overall, I think we’re going to see a continued push for more US-based manufacturing and job creation, similar to the previous administration’s approach. From an Indian pharma perspective, I don't ...

NTU Singapore is introducing two new undergraduate degree programmes in robotics and advanced chemical and pharmaceutical ...

Cipla’s FDA-compliant facilities and its investments in US-based units place it in a strong position to weather potential ...

Clarity Pharmaceuticals Ltd. (AU:CU6) has released an update. Clarity Pharmaceuticals has strengthened its production capabilities by signing ...

These projects cover a wide range of sectors, including Chemical/Renewable Energy, Steel, Aluminium, Food Processing, ...

The Pharma & Biotech market had a relatively muted month. There were a number of companies that experienced strong share ...

The government's new Rs 500 crore scheme for the medical device industry will not only boost domestic manufacturing but also ...

Evolving industry demands are driving the need for greater flexibility and innovation in processing equipment for ...

We are bullish on Avid's potential take-private deal by Ampersand and GHO, predicting value creation and optimistic about ...

The contract manufacturing industry has grown significantly as big ... It manufactures the products on behalf of ...